Interventional Cardiovascular Programs News Today

September 18, 2022—Medtronic announced the presentation of long-term results from the SYMPLICITY HTN-3 clinical trial. In the randomized control

Medtronic announced study data demonstrating significant blood pressure reduction with the Symplicity renal denervation system.

Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The LancetData a...

Investegate announcements from Amarin Corporation plc, New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

26.08.2022 - - Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses - - Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 ... Seite 1

-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European

Investegate announcements from Amarin Corporation plc, REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI

GuruFocus Article or News written by GuruFocusNews and the topic is about:

/PRNewswire/ -- An evidence-based approach to clinical trial oversight is key to the future of clinical trial oversight, according to Deepak Bhatt, MD and...